This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A S Search for Related Content PubMed PubMed Citation Articles by Wierzbicki, A S Social Bookmarking                         What's this?

Lipid-lowering drugs in lupus: an unexplored therapeutic intervention

Department of Chemical Pathology, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK Anthony.Wierzbicki{at}kcl.ac.uk

Lipid-lowering drugs have been shown to have profound actions beyond modulation of lipid profiles. Statins have been shown to reduce the levels of pro-inflammatory cytokines and markers of acute phase response including C-reactive protein and serum amyloid A. Fibrates have also shown to reduce interlukin-6 levels. Both groups of drugs seem to act through a peroxisomal proliferating activating receptor alpha mechanism to achieve these actions. In lupus, there is profound activation of cytokine production and the acute phase response and a markedly increased risk for the development of atherosclerosis. The role of lipid-lowering drugs in the management of both the acute and chronic sequelae of lupus needs to be explored.

Key Words: systemic lupus erythematosus • lipid • statin (HMG coA reductase inhibitor) • fibrate

Lupus, Vol. 10, No. 3, 233-236 (2001)
DOI: 10.1191/096120301666117984


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C Abud-Mendoza, H de la Fuente, E Cuevas-Orta, L Baranda, J Cruz-Rizo, and R Gonzalez-Amaro Therapy with statins in patients with refractory rheumatic diseases: a preliminary study Lupus, August 1, 2003; 12(8): 607 - 611. [Abstract] [PDF]